Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
67Cu-Sar-NTSR
- Development stage
- Preclinical
- Lead developer
- Accunovo Biotechnologies
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
67Cu-Sar-NTSR is an investigational, targeted radiotherapeutic (radioligand therapy) consisting of the beta-emitting radioisotope copper-67 (67Cu) chelated by a sarcophagine (Sar) cage moiety and conjugated to a neurotensin receptor 1 (NTSR1) targeting ligand. Developed by the University of North Carolina at Chapel Hill and licensed to Accunovo Biotechnologies, 67Cu-Sar-NTSR is designed to target NTSR1-expressing tumors, such as pancreatic ductal adenocarcinoma (PDAC) and prostate cancer (particularly PSMA-negative or neuroendocrine-transdifferentiated prostate cancer). The sarcophagine chelator provides high stability for the copper radiometal, preventing premature release and off-target toxicity. Upon binding to NTSR1 on cancer cells, the agent is internalized, and the beta emission from 67Cu induces DNA double-strand breaks, leading to tumor cell death. It is studied as a theranostic pair alongside its diagnostic counterpart, 64Cu-Sar-NTSR.
- Other names
- [67Cu]-Sar-NTSR67Cu-labeled sarcophagine-neurotensin receptor ligand
02
Targets
NTR1 (Nitroreductase-1)
Beyond the preview
Go deeper on 67Cu-Sar-NTSR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 67Cu-Sar-NTSR.